{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T07:05:01Z","timestamp":1782975901085,"version":"3.54.5"},"reference-count":0,"publisher":"AME Publishing Company","content-domain":{"domain":["amegroups.com"],"crossmark-restriction":false},"short-container-title":["Transl Breast Cancer Res"],"DOI":"10.21037\/tbcr-25-29","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:12:49Z","timestamp":1773213169000},"page":"28-28","update-policy":"https:\/\/doi.org\/10.21037\/ame_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutics and toxicity management of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: a narrative review"],"prefix":"10.21037","volume":"7","author":[{"given":"Hitomi","family":"Sakai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tsurutani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8611","published-online":{"date-parts":[[2026,7]]},"container-title":["Translational Breast Cancer Research"],"original-title":[],"link":[{"URL":"https:\/\/tbcr.amegroups.com\/article\/download\/112016\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:09:45Z","timestamp":1782972585000},"score":1,"resource":{"primary":{"URL":"https:\/\/tbcr.amegroups.com\/article\/view\/112016\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.21037\/tbcr-25-29","relation":{},"ISSN":["2218-6778"],"issn-type":[{"value":"2218-6778","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}